Septerna (SEPN) catalysts

Upcoming FDA decisions and readouts we track for Septerna, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 1 Rows last checked — 12 Sep 2026

FreeBioList tracks 1 upcoming catalyst for Septerna (SEPN, listed on Nasdaq). It concerns SEP-479 (Hypoparathyroidism (oral PTH1R agonist)).

First on the list: the Phase 1 readout for SEP-479 (Hypoparathyroidism (oral PTH1R agonist)), guided by the company to Q1 2027.

The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: SEPN
Next catalyst: Q1 2027
Type: Phase 1 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Septerna SEPN · Nasdaq	SEP-479	Hypoparathyroidism (oral PTH1R agonist)	Q1 2027 company guidance	Phase 1 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Septerna expects to report Phase 1 data from both the SAD and MAD cohorts in the first quarter of 2027." Source: 8-K exhibit 99.1, filed 10 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Eikon Therapeutics (EIKN)Non-squamous NSCLC (TLR7/8 agonist); Melanoma — first interim analysis; Advanced solid tumours (PARP1-selective); Advanced solid tumours (WRN helicase inhibitor

Also due in Q1 2027

aTyr Pharma (ATYR)Phase 2 readout for Efzofitimod, Q1 2027
Belite Bio (BLTE)PDUFA date for Tinlarebant, 12 Feb 2027
Ocugen (OCGN)Phase 3 readout for OCU400, Q1 2027
Arcutis Biotherapeutics (ARQT)PDUFA date for ZORYVE (roflumilast) cream 0.05%, 23 Feb 2027
Dyne Therapeutics (DYN)PDUFA date for z-rostudirsen (DYNE-251), 21 Jan 2027
Olema Pharmaceuticals (OLMA)Phase 3 readout for Palazestrant (OP-1250), Q1 2027